{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:04:36Z","timestamp":1790395476683,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,7]],"date-time":"2015-12-07T00:00:00Z","timestamp":1449446400000},"content-version":"vor","delay-in-days":3537,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2006,4]]},"DOI":"10.1038\/sj.ki.5000208","type":"journal-article","created":{"date-parts":[[2006,2,24]],"date-time":"2006-02-24T09:26:13Z","timestamp":1140773173000},"page":"1216-1221","source":"Crossref","is-referenced-by-count":126,"title":["Clinical benefit of enzyme replacement therapy in Fabry disease"],"prefix":"10.1016","volume":"69","author":[{"given":"F.","family":"Breunig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Weidemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Strotmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Knoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/sj.ki.5000208_bb0010","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"3733","article-title":"Alpha galactosidase deficiency: Fabry disease","author":"Desnick","year":"2001"},{"issue":"Suppl 2","key":"10.1038\/sj.ki.5000208_bb0015","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/01.ASN.0000016683.73778.78","article-title":"Natural history and treatment of renal involvement in Fabry disease","volume":"13","author":"Branton","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/sj.ki.5000208_bb0020","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/318809","article-title":"A phase 1\/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies","volume":"68","author":"Eng","year":"2001","journal-title":"Am J Hum Genet"},{"key":"10.1038\/sj.ki.5000208_bb0025","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1073\/pnas.97.1.365","article-title":"Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease","volume":"97","author":"Schiffmann","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/sj.ki.5000208_bb0030","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1038\/sj.ki.5000208_bb0035","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","article-title":"Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy","volume":"62","author":"Thurberg","year":"2002","journal-title":"Kidney Int"},{"key":"10.1038\/sj.ki.5000208_bb0040","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","article-title":"Long-term safety and efficacy of enzyme replacement therapy for Fabry disease","volume":"75","author":"Wilcox","year":"2004","journal-title":"Am J Hum Genet"},{"key":"10.1038\/sj.ki.5000208_bb0045","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1038\/sj.ki.5000208_bb0050","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1161\/01.CIR.0000091253.71282.04","article-title":"Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease","volume":"108","author":"Weidemann","year":"2003","journal-title":"Circulation"},{"key":"10.1038\/sj.ki.5000208_bb0055","first-page":"67","article-title":"Angiokeratoma corporis diffusum\u2014Fabry's disease","volume":"34","author":"Colombi","year":"1967","journal-title":"Helv Med Acta"},{"key":"10.1038\/sj.ki.5000208_bb0060","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","article-title":"Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course","volume":"81","author":"Branton","year":"2002","journal-title":"Medicine"},{"key":"10.1038\/sj.ki.5000208_bb0065","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1046\/j.1523-1755.2002.00097.x","article-title":"Patients with Fabry disease on dialysis in the United States","volume":"61","author":"Thadani","year":"2002","journal-title":"Kidney Int"},{"key":"10.1038\/sj.ki.5000208_bb0070","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0272-6386(00)70054-0","article-title":"Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury","volume":"35","author":"Ruggenenti","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/sj.ki.5000208_bb0075","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1365-2362.2004.01424.x","article-title":"Fabry disease: overall effects of agalsidase alfa treatment","volume":"34","author":"Beck","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"10.1038\/sj.ki.5000208_bb0080","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","article-title":"Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy","volume":"138","author":"Desnick","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1038\/sj.ki.5000208_bb0085","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJM199102073240607","article-title":"An atypical variant of Fabry's disease with manifestations confined to the myocardium","volume":"324","author":"von Scheidt","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1038\/sj.ki.5000208_bb0090","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1523-1755.2003.00160.x","article-title":"Fabry disease: detection of undiagnosed hemodialysis patients and identification of a \u2018renal variant\u2019 phenotype","volume":"64","author":"Nakao","year":"2003","journal-title":"Kidney Int"},{"key":"10.1038\/sj.ki.5000208_bb0095","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1161\/01.CIR.0000061952.27445.A0","article-title":"Early detection of Fabry cardiomyopathy by tissue Doppler imaging","volume":"107","author":"Pieroni","year":"2003","journal-title":"Circulation"},{"key":"10.1038\/sj.ki.5000208_bb0100","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1067\/mhj.2000.105105","article-title":"New insights in cardiac structural changes in patients with Fabry's disease","volume":"139","author":"Linhart","year":"2000","journal-title":"Am Heart J"},{"key":"10.1038\/sj.ki.5000208_bb0105","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1161\/01.CIR.0000012626.81324.38","article-title":"Prevalence of Anderson\u2013Fabry disease in male patients with late onset hypertrophic cardiomyopathy","volume":"105","author":"Sachdev","year":"2002","journal-title":"Circulation"},{"key":"10.1038\/sj.ki.5000208_bb0110","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0735-1097(02)02380-X","article-title":"Cardiac manifestations of Anderson\u2013Fabry disease in heterozygous females","volume":"40","author":"Kampmann","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1038\/sj.ki.5000208_bb0115","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/ndt\/18.1.7","article-title":"Enzyme replacement therapy for Fabry disease: proving the clinical benefit","volume":"18","author":"Breunig","year":"2003","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 84","key":"10.1038\/sj.ki.5000208_bb0120","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1046\/j.1523-1755.63.s84.5.x","article-title":"Fabry disease: diagnosis and treatment","volume":"63","author":"Breunig","year":"2003","journal-title":"Kidney Int"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815516384?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815516384?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T06:00:11Z","timestamp":1626847211000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815516384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["S0085253815516384"],"URL":"https:\/\/doi.org\/10.1038\/sj.ki.5000208","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1053678.505584","asserted-by":"object"}]},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2006,4]]}}}